Norconsult ASA (NORCO)
Oslo Stock Exchange · Norway · prices in NOK · close of 23 Oct 2026
Key indicators
| Last close | NOK 37.20 |
|---|---|
| 52-week range | 33.70 – 49.15 |
| Return, 1 month / 3 months | −2.1% / +0.4% |
| Return, 1 year / 3 years | −18.9% / – |
| Trend | Below its 200-day average |
| RSI (14) | 45 |
| Volatility (1 year) | 23.6% |
| Worst drawdown (1 year) | -27.2% |
| Average daily value traded | 10.84M NOK |
| Dividend yield | 4.8% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Norconsult is a Norwegian engineering and design consultancy based in Sandvika, near Oslo. It advises on and designs buildings, transport infrastructure, water and wastewater systems, energy facilities and environmental projects. Its clients include public authorities, municipalities and private developers, and it works across the Nordic countries and beyond. The firm brings together engineers, architects and specialists in planning, technical design and project management to take schemes from early studies through to construction.
Norconsult ASA trades under the code NORCO on the Oslo Stock Exchange in Norway, with its price quoted in Norwegian kroner (NOK). Our dividend records, which start in 2019, show payments in 3 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Norconsult ASA (NORCO) trades on the Oslo Stock Exchange in Norway. It last closed at NOK 37.20 on 23 October 2026.
Its price-based Market X-Ray is 53 out of 100 (a fair price profile), ranking 145 of 294 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 18.9% and over the last three months it rose 0.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Oslo Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 46 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -2.5% | ||
| From 52-week high | -23.5% | ||
| Momentum | 42 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | 0.4% | ||
| 6-month return | -3.7% | ||
| 12-month return, skipping the last month | -17.2% | ||
| Stability (higher is calmer) | 69 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 23.6% | ||
| Worst drawdown, 1 year (smaller is calmer) | -27.2% | ||
| Liquidity | 73 · Strong | Trades actively. | |
| Average daily value traded | 10.84M NOK | ||
| Zero-volume days | 0.0% | ||
| Income | 31 · Weak | Dividend is small or irregular. | |
| Dividend yield | 4.8% | ||
| Years with dividends | 3 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Income: Dividend is small or irregular.
Returns
| 1 week | −1.5% |
|---|---|
| 1 month | −2.1% |
| 3 months | +0.4% |
| 6 months | −3.7% |
| 1 year | −18.9% |
| 3 years | – |
| 5 years | – |
Signals
| 50-day / 200-day average | 38.16 / 38.15 |
|---|---|
| Golden / death cross (60 days) | Golden, 3 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.70 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 5 May 2026 | NOK 1.8000 |
| 6 May 2025 | NOK 1.7000 |
| 24 May 2024 | NOK 1.2000 |
| 14 May 2024 | NOK 1.2000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Oslo Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.